The Blog on eu-authorized-representative

EU Authorized Representative for Medical Devices and IVDs in Europe


For non-EU manufacturers, bringing medical devices or in vitro diagnostic devices into the European market involves more than product quality, technical documentation and regulatory preparation. Before any device is introduced to the European market, the manufacturer must appoint an EU Authorized Representative who is physically located in the European Union and legally recognised as the manufacturer’s official representative. This function is critical under the Medical Device Regulation and the In Vitro Diagnostic Medical Device Regulation as regulators require a responsible local entity to manage communication, supply documentation and assist with compliance obligations when needed. An eu-authorized-representative is not simply a name on a label. They serve as the legal presence of a non-EU manufacturer and play a vital role in ensuring market access, regulatory trust and ongoing post-market accountability.

Why an EU Authorized Representative Is Required


European regulations for medical devices aim to safeguard patients, healthcare providers and users by ensuring every product entering the market has a defined chain of responsibility. If a manufacturer operates outside the European Union, regulators cannot always interact with them as easily as they would with a locally established company. This is where the EU Authorized Representative becomes necessary. The representative offers a formal European presence and acts as the official contact for Competent Authorities, Notified Bodies and other regulatory parties.

Without appointing an authorised representative, a non-EU manufacturer cannot legally place medical devices or IVDs on the European market. This applies to a wide range of products, from simple low-risk devices to complex diagnostic technologies. This obligation applies before market entry, meaning the representative must be selected early in the compliance journey rather than as a last administrative step. For manufacturers planning European distribution, choosing the right EU Authorized Representative for Medical Devices and IVDs can directly affect registration readiness, documentation control and long-term regulatory stability.

The Written Mandate Between Manufacturer and Representative


The connection between the manufacturer and the EU Authorized Representative must be formalised through a written mandate. This mandate defines the tasks the representative is authorised to perform and confirms the obligations both parties must follow. It is a critical compliance record as it defines the scope of representation, responsibilities, communication roles and the actions required if compliance issues occur.

An unclear or weakly drafted mandate can cause uncertainty at critical moments, particularly during authority requests, inspections, complaint handling or corrective actions. A strong mandate should clearly describe how documents will be made available, how regulatory communication will be handled, how incident information will be shared and what happens if the manufacturer does not meet its duties. For this reason, the mandate should be prepared carefully and reviewed before device registration or market placement begins.

Label and Packaging Requirements


The name and address of the EU Authorized Representative must appear on the device label, packaging or related product information as required by the applicable regulation. This enables authorities, distributors, healthcare professionals and users to identify the local representative connected to the device. It also reinforces the representative’s role as the official European presence for a manufacturer located outside the European Union.

Accurate labelling is essential because incorrect or missing representative details can lead to compliance issues and possible delays in market access. Manufacturers should ensure that their artwork, instructions, declarations and registration information are aligned before products are released. If the representative changes, labelling and registration details may also need to be updated in a controlled and timely manner.

Documentation Review and Availability


A key responsibility of an EU Authorized Representative for Medical Devices and IVDs is to ensure that essential compliance documents are available and correctly prepared. This includes checking that the EU Declaration of Conformity exists, that technical documentation has been compiled and that the manufacturer has followed an appropriate conformity assessment route for the device type and risk class.

The representative may also be required to retain or access copies of technical files, declarations and Notified Body certificates. These records must remain accessible for inspection by Competent Authorities for the specified retention period after the last device is marketed. This places document control eu-authorized-representative at the core of the manufacturer–representative relationship. Manufacturers should maintain updated records and ensure that the representative can respond quickly if regulators request information.

Communication With Competent Authorities and Notified Bodies


The EU Authorized Representative acts as the official communication channel between the non-EU manufacturer and European regulatory authorities. If a Competent Authority requests information, samples, technical documentation or clarification, the representative is expected to support the response process. The representative may also liaise with Notified Bodies when necessary, particularly regarding certification, conformity assessments or corrective measures.

This communication function goes beyond simply passing messages. A reliable representative should understand regulatory expectations, keep accurate records and ensure that requests are handled within appropriate timelines. Late or incomplete replies can lead to serious consequences, including market limitations or additional regulatory scrutiny. Therefore, manufacturers should partner with a representative who has strong regulatory expertise and well-defined internal systems.

Post-Market Surveillance and Incident Support


Compliance for medical devices does not stop once the product reaches the market. After a device is in circulation, manufacturers must continuously monitor performance, complaints, incidents and safety indicators. The EU Authorized Representative has a role in supporting this post-market responsibility by passing complaints and incident information to the manufacturer without delay.

This is particularly critical when information originates from clinicians, patients, users, distributors or authorities. Timely communication helps the manufacturer assess whether further investigation, reporting, field safety action or corrective action is needed. An effective representative recognises that post-market surveillance goes beyond documentation. It plays a key role in patient safety, product enhancement and continued regulatory confidence.

Registration Responsibilities and EUDAMED


Under European regulatory systems, manufacturer and representative details must be registered as required. The EU Authorized Representative may support the registration of both the manufacturer and representative information in EUDAMED. Accurate registration enables authorities to identify responsible entities, review device data and maintain market supervision.

Manufacturers should prepare complete company details, device information, certificates and declarations before registration activities begin. Any mismatch between labelling, declarations, technical documentation and registration records may lead to delays or compliance concerns. The representative’s role helps ensure all required information is aligned and accessible when required.

When the Representative Must Take Action


An EU Authorized Representative also has duties if the manufacturer fails to meet regulatory obligations. If serious non-compliance occurs and the manufacturer does not correct the issue, the representative may need to end the mandate and inform relevant authorities and the Notified Body where applicable. This responsibility highlights that the role extends beyond administrative tasks.

The representative has legal accountability and cannot ignore major compliance failures. Manufacturers should therefore view the representative as a regulatory partner rather than a passive provider. Clear communication, regular document updates and defined responsibilities help avoid misunderstandings and minimise risk throughout the product lifecycle.

Choosing the Right EU Authorized Representative


Selecting an EU Authorized Representative should be done with care. Manufacturers should evaluate regulatory expertise, experience in medical devices and IVDs, document management capabilities, clear response processes and strong knowledge of European regulations. The representative should be able to support communication with authorities, maintain records and guide the manufacturer on practical compliance expectations.

Cost alone should not determine the choice. An ineffective representative may lead to delays, communication gaps and increased risk, whereas a strong representative can support confidence during market entry and beyond. The correct selection provides non-EU manufacturers with a reliable European presence and enables smoother regulatory management.

Conclusion


An EU Authorized Representative is a mandatory requirement for non-EU manufacturers aiming to introduce medical devices or IVDs into the European market. The role covers legal representation, document availability, regulatory communication, complaint management, registration assistance and intervention in cases of serious non-compliance. Under the Medical Device Regulation and In Vitro Diagnostic Medical Device Regulation, appointing an authorised representative is not optional and should be completed before market placement begins. By selecting a capable EU Authorized Representative for Medical Devices and IVDs, manufacturers can enhance compliance, protect patient safety and establish a solid foundation for long-term European market access.

Leave a Reply

Your email address will not be published. Required fields are marked *